乳腺癌生存率和发病率:伊朗西北部10年癌症登记数据

IF 1.6 Q4 ONCOLOGY
International Journal of Breast Cancer Pub Date : 2020-05-01 eCollection Date: 2020-01-01 DOI:10.1155/2020/1963814
Roya Dolatkhah, Mohammad Hossein Somi, Mohammad Asghari Jafarabadi, Mehrnaz Hosseinalifam, Sepideh Sepahi, Mina Belalzadeh, Marzieh Nezamdoust, Saeed Dastgiri
{"title":"乳腺癌生存率和发病率:伊朗西北部10年癌症登记数据","authors":"Roya Dolatkhah,&nbsp;Mohammad Hossein Somi,&nbsp;Mohammad Asghari Jafarabadi,&nbsp;Mehrnaz Hosseinalifam,&nbsp;Sepideh Sepahi,&nbsp;Mina Belalzadeh,&nbsp;Marzieh Nezamdoust,&nbsp;Saeed Dastgiri","doi":"10.1155/2020/1963814","DOIUrl":null,"url":null,"abstract":"<p><strong>Methods: </strong>Data were obtained from East Azerbaijan cancer registry database for the 10-year period between 2007 and 2016. Survival analysis was performed to calculate the breast cancer-specific survival proportions and mortality rates. Joinpoint trend analysis was performed to estimate the incidence trend of the cancer.</p><p><strong>Results: </strong>A total number of 4989 patients were recorded with primary diagnosis of breast cancer. Of them, we collected follow-up data for 1335 (1309 female and 26 male). The 10-year crude mortality rate was 3.34 (per 100,000). The one-, two-, three-, five-, and ten-year breast cancer-specific survival proportions were 0.92 (95% CI 0.91-0.93), 0.88 (95% CI 0.86-0.90), 0.84 (95% CI 0.83-0.86), 0.77 (95% CI 0.74-0.80), and 0.65 (95% CI 0.60-0.70), respectively. Over the study period, the age-standardized incidence rates increased from 21.68 to 36.99 (per 100,000) with an annual percentage change of 5.5 percent. Older individuals and males patients had significantly worse survival, and patients with high-grade tumors had significantly higher risk of mortality.</p><p><strong>Conclusion: </strong>A relatively better survival for breast cancer in East Azerbaijan, Iran, was observed compared to the overall breast cancer-specific survival proportions and mortality rates in the country. However, it is still poor compared to the developed countries indicating that inappropriate treatment modalities might have played a role on this.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2020 ","pages":"1963814"},"PeriodicalIF":1.6000,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1963814","citationCount":"28","resultStr":"{\"title\":\"Breast Cancer Survival and Incidence: 10 Years Cancer Registry Data in the Northwest, Iran.\",\"authors\":\"Roya Dolatkhah,&nbsp;Mohammad Hossein Somi,&nbsp;Mohammad Asghari Jafarabadi,&nbsp;Mehrnaz Hosseinalifam,&nbsp;Sepideh Sepahi,&nbsp;Mina Belalzadeh,&nbsp;Marzieh Nezamdoust,&nbsp;Saeed Dastgiri\",\"doi\":\"10.1155/2020/1963814\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Methods: </strong>Data were obtained from East Azerbaijan cancer registry database for the 10-year period between 2007 and 2016. Survival analysis was performed to calculate the breast cancer-specific survival proportions and mortality rates. Joinpoint trend analysis was performed to estimate the incidence trend of the cancer.</p><p><strong>Results: </strong>A total number of 4989 patients were recorded with primary diagnosis of breast cancer. Of them, we collected follow-up data for 1335 (1309 female and 26 male). The 10-year crude mortality rate was 3.34 (per 100,000). The one-, two-, three-, five-, and ten-year breast cancer-specific survival proportions were 0.92 (95% CI 0.91-0.93), 0.88 (95% CI 0.86-0.90), 0.84 (95% CI 0.83-0.86), 0.77 (95% CI 0.74-0.80), and 0.65 (95% CI 0.60-0.70), respectively. Over the study period, the age-standardized incidence rates increased from 21.68 to 36.99 (per 100,000) with an annual percentage change of 5.5 percent. Older individuals and males patients had significantly worse survival, and patients with high-grade tumors had significantly higher risk of mortality.</p><p><strong>Conclusion: </strong>A relatively better survival for breast cancer in East Azerbaijan, Iran, was observed compared to the overall breast cancer-specific survival proportions and mortality rates in the country. However, it is still poor compared to the developed countries indicating that inappropriate treatment modalities might have played a role on this.</p>\",\"PeriodicalId\":46159,\"journal\":{\"name\":\"International Journal of Breast Cancer\",\"volume\":\"2020 \",\"pages\":\"1963814\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2020-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/1963814\",\"citationCount\":\"28\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Breast Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/1963814\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/1963814","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 28

摘要

方法:数据来自2007年至2016年东阿塞拜疆癌症登记数据库。进行生存分析,计算乳腺癌特异性生存率和死亡率。采用联合点趋势分析估计肿瘤的发病趋势。结果:本组共4989例初诊乳腺癌患者。其中,我们收集了1335例(女性1309例,男性26例)的随访资料。10年粗死亡率为3.34(每10万人)。1年、2年、3年、5年和10年乳腺癌特异性生存率分别为0.92 (95% CI 0.91-0.93)、0.88 (95% CI 0.86-0.90)、0.84 (95% CI 0.83-0.86)、0.77 (95% CI 0.74-0.80)和0.65 (95% CI 0.60-0.70)。在研究期间,年龄标准化发病率从21.68上升到36.99(每10万人),年增长率为5.5%。老年人和男性患者的生存率明显较差,恶性肿瘤患者的死亡率明显较高。结论:与该国总体乳腺癌特异性生存率和死亡率相比,观察到伊朗东阿塞拜疆的乳腺癌生存率相对较高。然而,与发达国家相比,它仍然很差,这表明不适当的治疗方式可能在这方面发挥了作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Breast Cancer Survival and Incidence: 10 Years Cancer Registry Data in the Northwest, Iran.

Breast Cancer Survival and Incidence: 10 Years Cancer Registry Data in the Northwest, Iran.

Methods: Data were obtained from East Azerbaijan cancer registry database for the 10-year period between 2007 and 2016. Survival analysis was performed to calculate the breast cancer-specific survival proportions and mortality rates. Joinpoint trend analysis was performed to estimate the incidence trend of the cancer.

Results: A total number of 4989 patients were recorded with primary diagnosis of breast cancer. Of them, we collected follow-up data for 1335 (1309 female and 26 male). The 10-year crude mortality rate was 3.34 (per 100,000). The one-, two-, three-, five-, and ten-year breast cancer-specific survival proportions were 0.92 (95% CI 0.91-0.93), 0.88 (95% CI 0.86-0.90), 0.84 (95% CI 0.83-0.86), 0.77 (95% CI 0.74-0.80), and 0.65 (95% CI 0.60-0.70), respectively. Over the study period, the age-standardized incidence rates increased from 21.68 to 36.99 (per 100,000) with an annual percentage change of 5.5 percent. Older individuals and males patients had significantly worse survival, and patients with high-grade tumors had significantly higher risk of mortality.

Conclusion: A relatively better survival for breast cancer in East Azerbaijan, Iran, was observed compared to the overall breast cancer-specific survival proportions and mortality rates in the country. However, it is still poor compared to the developed countries indicating that inappropriate treatment modalities might have played a role on this.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信